Menlo Therapeutics is a clinical late-stage biopharmaceutical company in California that focuses on treatments of dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. Founded 2011 in Menlo Park, California, United States, Menlo Therapeutics is focused on large and growing markets in dermatology. It has two commercial products: AMZEEQ® and ZILXI™, which employ proprietary differentiated Molecule Stabilizing Technology (MST). This proprietary technology stabilizes hydrophobic molecules and leads to a surfactant and irritant-free formulation designed to maintain barrier function, improve tolerability and compliance. It leads to a low mechanical shear designed to enhance spreadability and has the capability to deliver unstable drugs that have been difficult to formulate topically. This technology enabled the development of the first topical minocycline.
The pipeline products of the company deal with prurigo nodularis, prurigo dermatitis, psoriasis and refractory chronic cough. Menlo Therapeutics has combined with Foamix Pharmaceuticals creating a leading biopharma company focused on the commercialization and development of therapeutics to serve patients in the dermatology space.
Vice President of Regulatory Affairs and Quality Assurance
Mark P. Joing
Vice President of Clinical Operations
Chief Executive Officer